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BACKGROUND: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a
key issue in the treatment of metastatic colorectal cancer (mCRC).
METHODS: Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble VEGF receptor 2
(sVEGFR-2) and thrombospondin-1 (TSP-1) were assessed by ELISA assay at different time points in a cohort of 25 patients
enroled in a phase II trial of GONO-FOLFOXIRI plus BV as first-line treatment of mCRC. VEGF:  2578A/C,  1498C/T,
 1154A/G,  634C/G and 936C/T; and VEGFR-2:  604A/G, þ1192C/T and þ1719A/T, polymorphisms were assessed in a total
of 54 patients.
RESULTS: Treatment with GONO-FOLFOXIRI plus BV determined a prolonged and significant reduction in plasma free, biologically
active VEGF concentration. Interestingly, VEGF concentrations remained lower than at baseline also at the time of PD. Conversely,
PlGF levels increased during the treatment if compared with baseline, suggesting a possible role in tumour resistance; moreover,
sVEGFR-2 increased at the time of PD, as well as TSP-1. No association of assessed polymorphisms with outcome was found.
CONCLUSION: Our study suggested the possible mechanisms of resistance to combined therapy in those patients with a progressive
disease to be tested in ongoing phase III randomised studies.
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In the last years, the management of metastatic colorectal cancer
(mCRC) has been relevantly changed by the availability of two
classes of biological drugs: the anti-vascular endothelial growth
factor (VEGF), bevacizumab (BV) and the anti-epidermal growth
factor receptor (EGFR), cetuximab and panitumumab (Labianca
et al, 2010). Although KRAS mutations are consistently associated
with reduced overall and progression-free survival (PFS) and
increased treatment failure rates among patients with advanced
colorectal cancer treated with anti-EGFR antibodies (Dahabreh
et al, 2011), no genetic and molecular markers for BV have been
found. Thus, the identification of these markers to predict or
monitor the efficacy of BV, as well as the characterisation of the
biological mechanisms below the onset of acquired resistance,
represent challenging fields with immediate spin-off for the clinical
practise (Barugel et al, 2009; Loupakis et al, 2010). The assessment
of circulating levels of pro- and anti-angiogenic factors may
provide insights into the BV-related modulation of the so-called
systemic ‘angiogenic balance’ (Brostjan et al, 2008; Pollina et al,
2008). However, the effect of the administration of BV on
circulating levels of VEGF is, so far, still debated. Both VEGF
and placental growth factor (PlGF) plasma levels were found
significantly increased after BV treatment in rectal cancer patients
enroled in small phase I and II trials that investigated the safety
and efficacy of BV (Willett et al, 2005, 2009), whereas Gordon et al
(2001) described a reduction of free serum VEGF in cancer
patients treated with escalating doses of BV, when compared with
basal concentrations. Similarly, the use of immunodepleted plasma
samples suggested that the anti-VEGF antibody significantly
reduces the free and biologically active VEGF concentrations
(Loupakis et al, 2007). Subsequently, other authors (Brostjan et al,
2008) reported similar findings in a larger number of colorectal
cancer patients treated with BV in a neoadjuvant setting,
confirming the increase of total but biologically inactive VEGF
because it was bound with the antibody. Interestingly, Kopetz et al
(2010) have recently observed that also plasma levels of other
proangiogenic factors, including PlGF, hepatocyte growth factor
and basic fibroblast growth factor (bFGF), are modulated by the
administration of BV, alone or combined with FOLFIRI.
The meaningful role of tumour microenvironment in determin-
ing the complex plot of signalling among normal and cancer cells
supports the pharmacogenetic approach, in the attempt to focus
on the contribution of the genetic background of the host to
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smechanisms of intrinsic or acquired resistance to the anti-
angiogenic drugs, for instance by modulating the secretion of
proangiogenic factors (e.g., VEGF) or soluble forms of their
receptors (e.g., sVEGFR-2; Pasqualetti et al, 2007). Although VEGF
single-nucleotide polymorphisms (SNPs) seem to have relevant
part in determining the risk, prognosis and survival of CRC
patients; till today their role as predictors of benefit from BV has
not been clearly demonstrated (Jain et al, 2009). In particular,
with regard to mCRC, a recent retrospective experience has
shown a significant correlation of VEGF  1498 TT variant of VEGF
 1498 C/T SNP with worse PFS in a population of mCRC patients
treated with FOLFIRI plus BV as first-line regimen (Loupakis et al,
2009).
A phase II study (FOIB trial) has recently investigated the safety
and the activity of GONO-FOLFOXIRI plus BV as first-line
treatment of mCRC patients. Encouraging results in terms of
response rate (RR: 77%), disease control rate (100%), PFS (median
PFS: 13.1 months) and overall survival (median OS: 30.9 months)
have been reported (Masi et al, 2010). Plasma samples were
collected during this clinical trial at various time points to measure
the levels of VEGF, PlGF, sVEGFR-2 and thrombospondin-1 (TSP-1).
Moreover, VEGF:  2578 A/C,  1498 C/T,  1154 A/G,  634 C/G
and 936 C/T; and VEGFR-2:  604 A/G, þ1192 C/T and þ1719
A/T, SNPs were also assessed. The aim of this study is to show the
pharmacodynamic and pharmacogenetic data during the response
to GONO-FOLFOXIRI plus BV treatment and at the time of PD, in
order to draw hypothesis generating, biological observations, to be
further tested in ongoing phase III randomised studies.
PATIENTS AND METHODS
Study population
The main inclusion criteria were the ones previously published
(Masi et al, 2010). Briefly, they were the following: histologically
confirmed diagnosis of colorectal adenocarcinoma; measurable
disease according to RECIST; metastatic disease deemed unresect-
able at baseline; previous adjuvant chemotherapy, ended more
than 12 months before the relapse. Enroled patients received
biweekly administrations of GONO-FOLFOXIRI plus BV
5mgkg
 1, for a maximum of 12 cycles (Masi et al, 2010).
Treatment was earlier discontinued in the case of disease
progression, unacceptable toxicity or consent withdrawal. Patients
underwent CT scan every 8 weeks for evaluation of tumour
response. After the 12th cycle, patients who had not signs of
disease progression continued to receive biweekly BV ±5FU/LV
until disease progression, unacceptable toxicity or their own
refusal. The protocol was approved by the local Ethics Committees
(EudraCT number 2006-001007-11), and patients provided their
written informed consent to receive the treatment and to
participate to translational analyses.
Blood samples collection and plasma PlGF, sVEGFR-2,
TSP-1 and VEGF detection
Venous blood was drawn at day 1 (baseline; d1), immediately
before the 2nd (day 15; d15), the 5th (day 57; d57) and the 12th
(day 155; d155) cycle of therapy and/or at the time of radiographic
progression (PD). Blood samples were immediately centrifuged at
41C and plasma fractions were divided in five equal aliquots,
frozen and stored at  801C until assayed.
VEGF, PlGF, sVEGFR-2, TSP-1 plasma levels were measured by
means of ELISA Quantikine DVE00, DPG00, DVR200 and DTSP10
Kits (R&D Systems, Minneapolis, MN, USA), respectively. The
optical density was determined using the microplate reader
Multiskan Spectrum (Thermo Labsystems, Milan, Italy) set to
450nm, with a wavelength correction set to 540nm.
To measure VEGF concentrations, plasma samples were immu-
nodepleted as previously described (Loupakis et al, 2007). Briefly,
plasma samples underwent to the immunodepletion using Protein
G-Sepharose 4 Fast Flow beads (Pharmacia Biotech, Uppsala,
Sweden). The beads were washed twice in PBS before being
reconstituted to 50% (v/v) protein G-sepharose in PBS. To deplete
plasma samples of BV and BV-bound VEGF, 100ml of protein G
slurry were added to 200ml of plasma samples and incubated at 41C
for 4h. After centrifugation (2min at 10000r.p.m.), 200mlo fp l a s m a
supernatants were removed and the immunodepletion was repeated
by the addition of 100ml of protein G slurry and overnight
incubation at 41C. Each plasma sample was than assayed for human
VEGF concentrations by the ELISA kit.
VEGF and VEGFR-2 genotyping
Blood samples (3ml) were collected at day 1 (pre-treatment) in
EDTA tubes. DNA extraction was performed using QIAamp DNA
Blood Mini Kit (Qiagen, Valencia, CA, USA). Real-time PCR–SNP
analysis of VEGF-A:  2578A/C (rs699947),  1498C/T (rs833061),
 1154A/G (rs1570360),  634C/G (rs2010963), 936C/T (rs3025039);
and of VEGFR-2,  604A/G (rs2071559), 1192C/T (rs2305948),
1719A/T (rs1870377), were performed using an ABI PRISM 7000
SDS (Applied Biosystems, Carlsbad, CA, USA) and validated
TaqMan SNP genotyping assays (Applied Biosystems; see Supple-
mentary Table A). PCR reaction was carried out according to the
protocol of the manufacturer.
Statistical analysis
As the pharmacodynamic part of the study was exploratory in
nature, no formal statistical hypothesis testing has been per-
formed. However, 25 patients have been enroled as suggested by
the entropy-based approach to sample size in translational clinical
trials (Piantadosi, 2005b). Although small sample sizes leave large
bias and high variance in the empirical entropy, modest increases
in sample size reduce the bias and variance substantially. Indeed,
large increases in the sample size reduce the bias and variance to
negligible levels, but most of the benefit can be achieved by sample
sizes around 10 to 20 (Piantadosi, 2005a). Comparisons between
concentrations at different time points were assessed by using the
two-sided non-parametric Wilcoxon test. Survival curves were
estimated using the Kaplan–Meier method. Cox proportional
hazard model was adopted to estimate and test the biological
parameters for their association with PFS. Patients who underwent
secondary resection were censored at the time of surgery, as well as
patients who had not progressed at the time of analyses. Results
were expressed as hazard ratios and relative 95% confidence
interval. All statistical calculations were performed using the
GraphPad Prism software package, version 5.0 (GraphPad Software
Inc., San Diego, CA, USA) and R software, version 2.10.0
(R Foundation for Statistical Computing, Vienna, Austria). Tests
for Hardy–Weinberg equilibrium and linkage disequilibrium
among the five analysed VEGF loci and the three VEGFR-2 loci
whose gametic phase is unknown was performed using PHASE and
Arlequin version 3.1 software (Swiss Institute of Bioinformatics,
Bern, Switzerland). The same software was used to calculate
haplotype frequencies according to maximum likelihood methods.
Relationship between VEGF-A and sVEGFR-2 expression and
genotypes were assessed by the non-parametric Kruskal–Wallis
test. The level of significance was set at Po0.05.
RESULTS
Patients’ characteristics
In all, 57 patients (34:23; M:F) were enroled in the phase II clinical
study (Masi et al, 2010). Main clinical characteristics at d1 are
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ssummarised in Table 1. At the time of pharmacodynamic and
pharmacogenetic analyses, that is at a median follow-up of 19.2
months, the median PFS was 13.1 months, whereas median OS was
not reached yet. Blood samples for genetic analyses were obtained
for all the enroled patients (Masi et al, 2010). Only a subgroup of
patients underwent multiple samplings, thus paired plasma
samples were available for 25 patients at d1 and at d15, for 24
patients at d57, for 21 patients at d155 and for 16 patients at the
time of PD.
Pharmacodynamic markers of GONO-FOLFOXIRI plus BV
treatment
Variations of investigated markers and comparisons with baseline
levels are summarised in Table 2. Neither basal levels of the
markers nor their variations during the treatment were related
with PFS. As OS data were yet undefined at the time of analyses,
correlations with OS were not calculated.
Free VEGF plasma levels decreased after GONO-
FOLFOXIRI plus BV treatment
Treatment with GONO-FOLFOXIRI plus BV determined a
significant reduction of VEGF plasma concentration after 15 days
if compared with d1 (P¼0.016; Figure 1A). Interestingly, the
VEGF level variation was independent of the baseline levels
(correlation coefficient: 0.105; P¼0.617; Figure 1B). Moreover,
VEGF levels at d57, at d155 and at the time of radiographic
progression were significantly lower than at baseline (P¼0.002,
P¼0.001 and Po0.0001, respectively; Figure 1A).
PlGF plasma concentrations increased during
GONO-FOLFOXIRI plus BV treatment
Differently from VEGF, PlGF concentrations significantly
increased at d57 (Po0.001) and at d155 (P¼0.019) if compared
with the levels of d1 samples (Figure 2A). Interestingly, a weak but
significant decrease was observed at the time of PD if compared
with d155 (P¼0.049) but still higher than its values at d1
(P¼0.044; Figure 2A).
Soluble VEGFR-2 and TSP-1 plasma levels increased at the
time of progression
sVEGFR2 constantly maintained its plasma concentration
throughout the treatment schedule and rapidly increased, although
not significantly, at the time of PD compared with d1 (P¼0.083)
and with d57 (P¼0.051; Figure 2B). However, a wide variability of
sVEGFR-2 levels was observed at the time of PD. Interestingly,
although in a subgroup of patients sVEGFR-2 levels did not vary
between d155 and PD, in another subgroup a significant increase
was observed at the time of PD, compared with d155. The mean
variation was significantly different between such subgroups
( 6.1% vs þ143.50%; Po0.0001; see Supplementary Figure A).
Figure 2C showed that TSP-1 decreased, if compared with d1, after
5 months of treatment (d155) with a trend towards significance
(P¼0.059), whereas significantly increased at the time of
progression if compared with d155 (P¼0.049).
VEGF and VEGFR-2 genotypes are not related to PFS and
plasma protein expression
Table 3 shows the frequencies of VEGF and VEGFR-2 SNPs. The
estimated frequencies of haplotypes for both VEGF and VEGFR-2
has been also calculated (see Supplementary Table B). None of the
analysed genotypes was significantly related to PFS (Table 3).
Allelic distributions for VEGF:  2578C/A,  1498C/T,  1154G/A
and 936C/T; and the three VEGFR-2 SNPs was in Hardy–Weinberg
equilibrium (available as Supplementary Table C). VEGF 936C/T
SNP was in strong linkage disequilibrium with VEGF:  2578C/A,
 1498C/T,  1154G/A and  634C/G, as well as VEGFR-2  604A/G
with VEGFR-2 1192C/T and 1719T/A SNPs (available as Supple-
mentary Table D). Plasma VEGF levels at baseline were not
influenced by any of the studied VEGF SNPs; similarly, no
relationship was observed between baseline sVEGFR-2 plasma
levels and analysed VEGFR-2 SNPs (Table 4).
DISCUSSION
The introduction of novel targeted therapies, such as BV and
cetuximab, a monoclonal antibody against the EGFR, increase the
possible treatments in mCRC. Cetuximab, as single agent,
Table 1 Patients’ characteristics
Characteristics N %
No. of patients 57 —
Age (median; range) 61 (34–75)
Sex (males/females) 34/23 60/40
ECOG PS (0–1/2) 54/2 95/5
Primary tumor (colon/rectum) 41/16 72/28
Resected primary tumor (yes/no) 44/13 77/23
Previous adjuvant chemotherapy (yes/no) 5/52 9/91
Sites of disease (single/multiple) 33/24 58/42
Synchronous metastases (yes/no) 49/8 86/14
Liver-only metastases (yes/no) 30/27 53/47
Abbreviation: ECOS PS¼Eastern Cooperative Oncology Group Performance Status
Scale.
Table 2 Modulation of investigated markers by treatment
Baseline Day 15 Day 57 Day 155 PD
Mean
(pgml
 1)
Median
(pgml
 1)
Mean
(pgml
 1)
Median
(pgml
 1)
%o f
baseline
median
values
Mean
(pgml
 1)
Median
(pgml
 1)
%o f
baseline
median
values
Mean
(pgml
 1)
Median
(pgml
 1)
%o f
baseline
median
values
Mean
(pgml
 1)
Median
(pgml
 1)
%o f
baseline
median
values
VEGF 86.32 57.68 49.23 39.96 61.47* 42.73 39.49 60.53** 39.38 36.66 38.80** 37.47 37.21 54.30***
PlGF 33.87 34.87 — — — 53.72 52.56 179.88*** 45.36 46.89 142.82* 39.32 40.19 119.2
sVEGFR-2 4179.05 4163.60 — — — 4247.80 4244.00 100.81 4514.40 4234.10 99.41 6641.60 4708.40 107.91
TSP-1 451.52 461.31 — — — 432.55 483.94 98.13 380.87 391.74 86.15 568.21 479.55 167.79
Abbreviations: PlGF¼placental growth factor; sVEGFR-2¼soluble vascular endothelial growth factor receptor 2; VEGF¼vascular endothelial growth factor;
TSP-1¼thrombospondin-1. Po0.1; *Po0.05; **Po0.01; ***Po0.001 compared with baseline level.
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mCRC patients resistant to chemotherapy, whereas its combina-
tion with irinotecan significantly prolongs PFS compared with the
antibody alone (4.1 months vs 1.5 months). Moreover, the addition
of cetuximab increased the RR of FOLFOX-4 in first-line treatment
of mCRC (Labianca et al, 2010). However, the benefits of anti-
EGFR monoclonal antibody treatment of advanced colorectal
cancer may be limited to patients without KRAS mutations
(Dahabreh et al, 2011). At present, BV is approved for the
treatment of mCRC in association with a fluoropyrimidine-based
chemotherapy and without any molecular restriction (Labianca
et al, 2010). Indeed, no biomarkers have been identified, till today,
as predictors of benefit from BV. At the same time, no tools are
currently available to quantify the contribution of anti-angiogenic
strategies, and in particular of VEGF blockade, to the activity of
conventional cytotoxic drugs. Although the principal aim of
biomarker studies in patients receiving BV is to identify those
patients who will benefit from the treatment, equally the detection
of the onset of drug resistance and the factors mediating this
resistance is increasingly important (Murukesh et al, 2010), given
recent data supporting the continuation of treatment with VEGF
inhibitors beyond PD (Saltz et al, 2008).
Waiting for a consistent contribution from translational
research to optimise the use of BV, the current priority in clinical
research is focused on whether there could be a molecular
biomarker associated to the response or resistance to the
combined therapies (Shaked et al, 2005). In this phase II study,
we have tried to contribute to the debate on this key issue
measuring plasma levels of VEGF, PlGF, sVEGFR-2 and TSP-1
during the treatment and at the time of PD. Moreover, we have
focused our exploratory investigation on the possible relationships
between the genetic background and PFS of the patients, by
assessing the VEGF:  2578 A/C,  1498 C/T,  1154 A/G,  634 C/G
and 936 C/T; and VEGFR-2:  604 A/G, þ1192 C/T and þ1719
A/T SNPs. However, because of the combined treatment adopted
in the study and the lack of an appropriate control group, remarks
suggested by the present experience are not directly attributable to
the administration of the anti-angiogenic drug alone, but should
be referred to the global treatment, including the triplet plus BV.
Indeed, such exploratory analyses have been performed to draw
hypothesis generating, biological observations, to be further tested
in two ongoing phase III randomised studies in the first- (TRIBE
trial, NCT00719797; http://www.clinicaltrials.gov) and second-line
treatment of mCRC patients (BEBYP trial, NCT00720512;
http://www.clinicaltrials.gov).
The transition from laboratory to clinic, and frequently back
again, is usually guided by small targeted studies rather than large
clinical trials. These translational trials form a bridge between
ideas developed in the laboratory and clinical development.
However, the outcome used for a translational trial is a target or
biological marker, which itself may require additional validation as
part of the study. The biological signal, such as a change in levels
of a protein or the activity of some enzymes, has to reveal
promising changes in direction and magnitude for proof of
principle, and to support further clinical development (Piantadosi,
2005a). Indeed, numerous examples have been recently published
in the scientific literature that support the importance of small
translational trials to proceed with the scientific knowledge about
biomarkers related to BV-based therapies and to develop them for
future clinical trials. For example, Brostjan et al (2008) showed
significant variations of VEGF and TSP-1 plasma levels after
treatment with BV in 19 patients, whereas Yang et al (2008)
correlated some angiogenic markers (CD31 and PDGFR-b) and the
response to neoadjuvant BV in 21 patients with breast cancer.
Moreover, recently Jain’s group has published significant evi-
dences of the up-regulation of SDF1a, CXCR4, CXCL6 and
neuropilin 1 after treatment with BV in just 12 rectal cancer
patients (Xu et al, 2009), confirming the importance of small
translational trial to identify a novel but ‘necessary and critical
insight for guiding further therapy’ (Xu et al, 2009).
This study explored how bevacizumab modulates the so called
‘angiogenic balance’, by following plasma variations of some
proteins, related to the angiogenic process. First of all, our study
definitively proved and confirmed the preliminary results obtained
both from our (Loupakis et al, 2007) and other laboratories
(Gordon et al, 2001; Brostjan et al, 2008), concerning the decrease
of biologically active free VEGF levels after the first administration
of a BV-containing regimen, as measured by ELISA assay on
immunodepleted plasma samples. Moreover, for the first time, our
data demonstrated that the triplet plus BV was able to significantly
reduce VEGF plasma levels independently from the baseline
concentrations, suggesting that the standard dose of BV is able to
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Figure 1 Comparisons between immunodepleted plasma VEGF levels at
different time points (A) and correlation between baseline (d1) and d15
VEGF levels (B). Columns and bars, mean values ±s.d., respectively.
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Furthermore, VEGF concentrations were maintained lower than
baseline not only during the treatment, but also at the time of PD,
clearly suggesting that the acquired resistance to the treatment is
not driven, at least in our clinical and experimental settings, by the
loss of the ability of the treatment to suppress free VEGF
circulating levels. These data are in line with preclinical findings
showing that resistance to VEGF pathway inhibitors could occur
through VEGF-independent mechanisms, such as the upregulation
of other proangiogenic factors (Crawford et al, 2009; Ferrara,
2010), the cooption of existing vessels or the selection of resistant
tumour cell clones (e.g., for the lack of p53; Crawford & Ferrara,
2009). To investigate the changes of proangiogenic levels of growth
factors other than VEGF, during the response and the therapeutic
resistance to the treatment with BV, we focused our attention on
PlGF. Unlike VEGF, PlGF concentrations significantly increased at
day 57 and at day 155 if compared with baseline, suggesting a
possible role of PlGF in supporting tumour neovascularisation in
the absence of VEGF. Such results are consistent with the
experience by Kopetz et al (2010), who demonstrated that before
PD, several proangiogenic factors significantly increased, including
the PlGF, bFGF, hepatocyte growth factor and the stromal-derived
factor-1 (Kopetz et al, 2010). A rapid increase in PlGF levels
following the administration of BV was also reported by Willett
et al (2009) in a series of 32 patients with locally advanced rectal
cancer, enroled in a phase I/II trial. However, the real role of PlGF
in tumour angiogenesis is still highly debated as recently pointed
out by Bais et al (2010) who demonstrated that, independently of
the status of the VEGF-A pathway, PlGF does not have a significant
role in angiogenesis during primary tumour growth in mice, as
proven by the lack of angiogenesis and tumour inhibition by anti-
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Figure 2 Comparisons between PlGF (A), sVEGFR-2 (B) and TSP-1 (C) plasma concentrations at different time points. Columns and bars, mean values
±s.d., respectively.
Table 3 Frequency distributions of VEGF and VEGFR-2 SNPs and PFS
SNP Genotype N
Median PFS
(months) Log rank test
VEGF SNPs
 2578C/A CC 22 10.4 P¼0.9813
AC 22 13.1
AA 13 10.8
 1498T/C TT 22 10.4 P¼0.9503
CT 22 13.1
CC 13 10.8
 1154G/A GG 8 10.8 P¼0.3398
AG 19 13.4
AA 30 10.4
 634G/C GG 26 13.4 P¼0.8300
CG 18 10.5
CC 13 16.2
936C/T CC 43 11.8 P¼0.7378
CT 13 10.8
TT 1 22.3
VEGFR-2 SNPs
 604A/G AA 15 20.7 P¼0.3224
AG 29 12
GG 13 9.9
1192C/T CC 51 11.8 P¼0.9314
CT 6 14.7
TT 0 —
1719A/T AA 1 20.7 P¼0.4762
AT 13 16.2
TT 43 10.8
Abbreviations: PFS¼progression-free survival; SNPs¼single-nucleotide polymorph-
isms; VEGF¼vascular endothelial growth factor; VEGFR-2¼VEGF receptor 2.
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role of PlGF in tumour neovascularisation, as PlGF blockage
inhibits vessel abnormalisation in certain tumours, thus enhancing
VEGF-targeted inhibition (Van de Veire et al, 2010). On the basis
of our experimental data, it cannot be excluded that PlGF
contributes to the emergence of an early tumour-driven escape
to the anti-VEGF therapy in a certain subgroup of patients.
Another interesting finding of our study is that although median
sVEGFR-2 levels did not significantly increase at the time of PD,
two distinct subsets of patients were identified at such time point.
In fact, while in eight patients sVEGFR-2 levels did not vary
( 6%), in the others an impressive average increase (þ143.5%)
was observed. These results led to hypothesise that sVEGFR-2
levels at the time of PD on BV-containing therapies may
distinguish two different populations of the patients with different
patterns of angiogenesis-related phenotypic modifications. The
increase of sVEGFR-2 may be related to the switch on of activated
endothelial cells or progenitors at the cancer metastatic sites, thus
corroborating the contribution of tumour’s microenvironment as
well as of other host’s tissues to the late onset of acquired
resistance (tumour and host-driven escape). In fact, in vitro
studies have determined that sVEGFR-2 can be found in the
conditioned media of proliferating mouse and human endothelial
cells, but not of colon cancer cells (e.g., HT-29; Ebos et al,
2008), thus suggesting that it may be secreted, similar to soluble
VEGFR-1, or proteolytically cleaved from the cells of tumour
microenvironment (Ebos et al, 2004). Moreover, recent in vitro
studies indicated the possibility of a VEGF-mediated sVEGFR-2
downregulation from the cell surface. Furthermore, plasma
sVEGFR-2 decrease was mediated largely by tumour-derived
VEGF (Ebos et al, 2008). These data may indirectly confirm that
BV is still effective in neutralising the free VEGF at the time
of PD, contributing, with the other sources, to the increase of
sVEGFR-2.
The identification of each angiogenic balance of the patient
between endogenous pro- and anti-angiogenic factors at the time
of PD might also help to identify new molecular markers and to
personalise subsequent treatments, by choosing the most tailored
anti-angiogenic strategy. In colorectal cancer, the role of TSP-1
seems to depend on tumour stage, whereas in patients bearing
primary tumours, high levels of TSP-1 correlate with higher
survival rates (Maeda et al, 2000, 2001). The high expression of
TSP-1 in patients with colorectal liver metastasis leads to poor
prognosis (Sutton et al, 2005), suggesting that the protective role
conferred by inhibition of angiogenesis is overcome when cancer
cells spread beyond their primary niche (Morandi, 2009).
Resistance to the anti-angiogenic effect of TSP-1 has been
associated to the selection of angiogenic tumour phenotypes
expressing high levels of angiogenic inducers, which would
overcome the inhibitory effects of TSP-1 (Fontana et al, 2005).
Our findings, showing an increase of TSP-1 at the time of
progression, seem to confirm the previously published data and
support the hypothesis of a failure of TSP-1 angiostatic
characteristic, favouring vessel quiescence, due to the increase of
other pro-angiogenic factors such as PlGF.
Because of the exploratory nature of our clinical experience,
the small sample size, as well as the high RR, further investigations
are greatly needed to allow correlations with the outcome. TRIBE
and BEBYP phase III trials will provide wider series of patients
to validate the present results. In this view, our pilot pharmaco-
genetic analyses have tried to correlate the PFS with any of the
studied VEGF and VEGFR-2 gene genotypes without any relevant
results. The 936T allele has been associated with an increased
risk (Bae et al, 2008), advanced stage of disease (Chae et al, 2008),
worse survival (Kim et al, 2008), whereas other studies did not
demonstrate any correlation with tumour size, grade and stage
(Hofmann et al, 2008) in patients with colorectal cancer. The  634
C allele was predictive of decreased risk (Chae et al, 2008) and
better survival (Kim et al, 2008), and was not related with tumour
size, grade and stage (Hofmann et al, 2008). Recently, the  1154
G/A and  460C/T SNPs lacked to show any influence on VEGF
mRNA expression in colorectal tumours and susceptibility to
sporadic colon cancer (Cacev et al, 2008). Interestingly, in an
Italian population a reduced risk for colon cancer was associated
with  2578C/A and  2578C/C VEGF SNPs (Maltese et al,
2009). Although no published data are currently available in
indexed literature on the role of VEGF and VEGFR-2 SNPs in
predicting the response and outcome related to BV treatment
in colorectal cancer, a recent retrospective experience has shown a
significant correlation of VEGF  1498 TT variant of VEGF  1498
C/T SNP with worse PFS in a population of mCRC patients
treated with FOLFIRI plus BV as first-line regimen (Loupakis et al,
2009).
In conclusion, our study has successfully characterised the
modulation of various biomarkers during GONO-FOLFOXIRI plus
BV treatment, suggesting some possible mechanisms of resistance
to the combined therapy. Such findings will be useful to better
draw further pharmacodynamic tests in ongoing phase III
randomised studies.
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Table 4 VEGF and VEGFR2 SNPs and relative plasma protein levels
SNPs Genotype N
Mean baseline
plasma levels
(pgml
 1) s.d.
Kruskal–
Wallis
statistic (H)
Kruskal–
Wallis
test
VEGF SNPs and VEGF plasma levels
 2578C/A CC 11 85.66 80.04 0.1405 P¼0.9322
AC 9 85.40 57.77
AA 5 89.40 67.94
 1498C/T TT 11 85.66 80.04 0.08018 P¼0.9607
CT 9 99.62 70.25
CC 5 63.81 20.03
 1154A/G GG 2 143.3 89.39 2.962 P¼0.2274
AG 10 84.71 54.38
AA 13 78.79 74.97
 634C/G GG 9 94.94 57.05 2.046 P¼0.3594
CG 11 69.10 47.23
CC 5 108.7 116.7
936C/T CC 19 76.12 43.64 0.9437 P¼0.6239
CT 5 133.0 123.0
TT 1 46.42 0.0
VEGFR2 SNPs and sVEGFR2 plasma levels
 604A/G AA 10 4316.5 46.51 3.789 P¼0.1504
AG 10 4080.5 70.25
GG 5 4100.5 49.16
1192C/T CC 22 4178.0 61.32 — P¼0.8672
a
CT 3 4186.0 60.35
TT 0— —
1719A/T TT 18 4141.0 64.71 2.402 P¼0.3009
AT 6 4234.5 40.62
AA 1 4533.5 0.0
Abbreviations: PFS¼progression-free survival; SNPs¼single-nucleotide polymor-
phisms; VEGF¼vascular endothelial growth factor; VEGFR-2¼VEGF receptor 2.
aMann–Whitney test.
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